What do systematic reviews say?

Proportion of participants with ≥ 1 non‐serious adverse events ‐ not reported · adults with biliary sphincter of Oddi dysfunction

Proportion of participants with ≥ 1 non‐serious adverse events ‐ not reported · adults with biliary sphincter of Oddi dysfunction

Proportion of participants with ≥ 1 non‐serious adverse events ‐ not reported · adults with biliary sphincter of Oddi dysfunction

Number of adverse events requiring discontinuation of treatment ‐ not reported · treating infections in people with neutropenia or neutrophil dysfunction

Serious adverse events related to the use of physical restraints ‐ not measured · older people in all long‐term care settings

Specific adverse events: gastrointestinal perforations or fistulae ‐ not reported · women with recurrent or FIGO stage IVB cervical cancer

Adverse events of medication, leading to discontinuation or significant morbidity · people with discoid lupus erythematosus

Minor adverse events not leading to withdrawal of treatment · pityriasis rosea

Adverse events as N of participants with at least one adverse event objective · patients with schizophrenia

Adverse effects/events: at least 1 adverse effect ‐ as defined by individual studies. · patients with schizophrenia

Adverse events as N of participants with at least one adverse event objective · patients with the treatment of cocaine dependence

Adverse events associated with the use of anticoagulants (e.g. bleeding) ‐ not measured · sickle cell disease

Risk of serious adverse events, including those that may be complications of the common cold · adults and children with colds and/or upper respiratory infections

Non‐serious local adverse events (low risk of bias) live attenuated HAV vaccine ICH‐GCP 1997 · patients with preventing hepatitis A.

Changes in microbiome in oral cavity, nasal cavity, oro- or nasopharynx · Patients without suspected or confirmed COVID-19 infection undergoing aerosol-generating procedures (AGPs), and the healthcare workers…

Adverse events 1 mg morphine vs 2 mg morphinePercentage of participants with any adverse event · patients undergoing knee arthroscopy

Non‐serious systemic adverse events (low risk of bias) live attenuated HAV vaccine ICH‐GCP 1997 · patients with preventing hepatitis A.

Non‐serious local adverse events (all included studies) live attenuated HAV vaccine ICH‐GCP 1997 · patients with preventing hepatitis A.

Adverse events such as transient discolouration, altered taste, allergic reaction, hypersensitivity · People undergoing aerosol-generating procedures (AGPs) in a dental setting

Adverse events 1 mg morphine vs 4 mg/5 mg morphinePercentage of participants with any adverse event · patients undergoing knee arthroscopy